Steve O’Brien - The Consciousness Library

Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.

J Psychopharmacol December 13, 2021 Ben Sessa, Jacob S. Aday, Steve O’Brien et al. 18 citations

BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although...

DOI: 10.1177/02698811211055809 Ecstasy Molly 3 4-methylenedioxymethamphetamine +16

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.

J Psychopharmacol February 18, 2021 Ben Sessa, Laurie Higbed, Steve O’Brien et al. 123 citations

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.

DOI: 10.1177/0269881121991792 Alcohol use disorder Aud Alcoholism Alcohol addiction +19

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

BMJ Case Rep July 15, 2019 Ben Sessa, Chloe Sakal, Steve O’Brien et al. 55 citations

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

DOI: 10.1136/bcr-2019-230109 Full text Psychedelic therapy Alcohol use disorder MDMA Therapy MDMA-Assisted Psychotherapy +14

Papers

Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.